Lamas Díaz, María JesúsFernández Ferreiro, AnxoCampos Toimil, ManuelBlanco Dorado, Sara2020-09-252021-06-052020http://hdl.handle.net/10347/23302Voriconazole is an antifungal agent used in aspergillosis and in fluconazole-resistant Candida spp. infections. Voriconazol is mainly metabolized by cytochrome 2C19 wich is highly polymorphic. A significant portion of patients fail to achieve therapeutic drug concentrations, with a consequently increased risk of therapeutic failure. In this work, the use of voriconazole in the real life clinical setting was studied and a HPLC method for the pharmacokinetic determination of voriconazole was developed. In addition, the factors of voriconazole pharmacokinetic variability were evaluated demonstrating the importance of CYP2C19 pharmacogenetics and pharmacokinetic drug-drug interactions.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/VoriconazolFarmacogenéticaFarmacocinéticaMedicina personalizadaMaterias::Investigación::32 Ciencias médicas::3208 Farmacodinámica::320809 Procesos metabólicos de los medicamentosMaterias::Investigación::32 Ciencias médicas::3209 Farmacologíadoctoral thesisopen access